Damora Therapeutics (DMRA) Other Non-Current Liabilities (2024 - 2026)
Damora Therapeutics' (DMRA) quarterly Other Non-Current Liabilities came in at $27000.0 in Q1 2026, down 40.0% YoY from $45000.0 in Q1 2025, and down 66.67% on a QoQ basis from $81000.0 in Q4 2025.
Damora Therapeutics (DMRA) Other Non-Current Liabilities (2024 - 2026) Analysis & Trends
Damora Therapeutics (DMRA) has 3 years of Other Non-Current Liabilities data on file, last reported at $27000.0 in Q1 2026.
- Quarterly Other Non-Current Liabilities fell 40.0% year-over-year to $27000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $27000.0 (down 40.0% YoY) and the FY2025 annual result came in at $81000.0, up 88.37% from the prior year.
- Other Non-Current Liabilities fell to $27000.0 in Q1 2026, from $81000.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $81000.0 in Q4 2025 to a low of $27000.0 in Q1 2026.
- A 3-year average of $49000.0 and a median of $47000.0 in 2025 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2025 — Other Non-Current Liabilities jumped 88.37% — and 2026, when it plunged 40.0%.
- Tracing DMRA's Other Non-Current Liabilities over 3 years: stood at $43000.0 in 2024, then jumped by 88.37% to $81000.0 in 2025, then slumped by 66.67% to $27000.0 in 2026.
- The last three Other Non-Current Liabilities figures came in at $27000.0 (Q1 2026), $81000.0 (Q4 2025), and $49000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Damora Therapeutics | 1.92 Bn | 1.38 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.53 Mn |
| Mar 31, 2026 | 27,000.00 |
| Dec 31, 2025 | 81,000.00 |
| Sep 30, 2025 | 49,000.00 |
| Jun 30, 2025 | 49,000.00 |
| Mar 31, 2025 | 45,000.00 |
| Dec 31, 2024 | 43,000.00 |